Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained

By HEOR Staff Writer

January 27, 2026

On December 9, 2025, the Board of Directors of Zorginstituut Nederland (decision reference 2025027072) approved amendments to the Beleidsregels risicoverevening for 2022, 2023, 2024, and 2025. These changes, published in Staatscourant 2026 nr. 967 on January 19, 2026, correct te...
Characterizing Burnout in Health Professionals: Insights from the BEATS Study in Portugal

By João L. Carapinha

Burnout Health Professionals: Join the BEATS Study Call Burnout health professionals in Portugal are invited to participate in the BEATS study, an initiative by the Portuguese Laboratory for Healthy Work Environments. Titled "B...
Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investments and Trends

By HEOR Staff Writer

Latin America Pharma Growth is surging as a high-growth engine for Boehringer Ingelheim, with double-digit market expansions outpacing mature regions like Europe, according to D...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance recommends dupilumab as an add-on maintenance therap...
Accelerating FAST-EU Clinical Trials

By HEOR Staff Writer

FAST-EU Clinical Trials Launch with 70-Day Target The FAST-EU clinical trials pilot, known as Facilitating and Accelerating Strategic Clinical Trials in the EU, is a one-year voluntary initiative by the
NICE Endorses Talazoparib Enzalutamide for Prostate Cancer Treatment

By HEOR Staff Writer

January 23, 2026

NICE Backs Talazoparib-Enzalutamide for Advanced Prostate Cancer The National Institute for Health and Care Excellence (NICE) has recommended talazoparib enzalutamide prostate cancer treatment, featuring talazoparib (...
View All News
Search By Category

Syenza's Top Picks

CHMP Meeting Highlights: December 2025 Advances in New Medicines Approvals

2025 China Drug Catalog Boosts Access with 114 New Drugs and Innovative Solutions

Eloralintide Obesity Treatment: Phase 2 Trial Reveals Significant Weight Loss Potential

WHO Guidelines Set New Standard for GLP-1 Obesity Therapies in Adults

Medical Schemes Affordability Crisis: Insights from the CMS Annual Report 2024/25

AI Chatbot Delusions: Navigating the Risks of Validation in Mental Health

Advancing EU Health Technology Assessment: Key Priorities in the HTACG Draft Annual Work Programme 2026

Latest

Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained

By HEOR Staff Writer

January 27, 2026

On December 9, 2025, the Board of Directors of Zorginstituut Nederland (decision reference 2025027072) approved amendments to the Beleidsregels risicoverevening for 2022, 2023, 2024, and 2025. These changes, published in Staatscourant 2026 nr. 967 on January 19, 2026, correct te...

Latest

Characterizing Burnout in Health Professionals: Insights from the BEATS Study in Portugal

By João L. Carapinha

Burnout Health Professionals: Join the BEATS Study Call Burnout health professionals in Portugal are invited to participate in the BEATS study, an initiative by the Portuguese Laboratory for Healthy Work Environments. Titled "B...

Latest

Latin America Pharma Growth: Boehringer Ingelheim’s Strategic Investments and Trends

By HEOR Staff Writer

Latin America Pharma Growth is surging as a high-growth engine for Boehringer Ingelheim, with double-digit market expansions outpacing mature regions like Europe, according to D...

Latest

NICE Endorses Dupilumab for Eosinophilic COPD Treatment

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance recommends dupilumab as an add-on maintenance therap...

Global Updates

Sandoz Biosimilars Strategy: Capturing Market Opportunities for Affordable Healthcare

By HEOR Staff Writer

January 23, 2026

Sandoz's Strategic Momentum in Biosimilars and Generics Sandoz's biosimilars strategy, as highlighted during the company's presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlines its prog...

Global Updates

Long-Term Benefits of Composite Treatment Targets in Type 2 Diabetes Management

By HEOR Staff Writer

January 21, 2026

Sustained Composite Treatment Targets Enhance Clinical and Economic Outcomes in Type 2 Diabetes A recent modeling study examines the long-term benefits of achieving

Global Updates

Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...

Global Updates

Childhood Immunization Reforms: Aligning U.S. Schedules with Global Standards

By João L. Carapinha

January 7, 2026

Aligning U.S. Childhood Immunization Schedules with International Benchmarks Recent childhood immunization reforms by the U.S. Centers for Disease Control and Prevention (CDC) follow a presidential directive...

Europe

View All
Risicoverevening Policy Updates: Key Amendments for 2022-2025 Explained

By HEOR Staff Writer

January 27, 2026

On December 9, 2025, the Board of Directors of Zorginstituut Nederland (decision reference 2025027072) approved amendments to the Beleidsregels risicoverevening for 2022, 2023, 2024, and 2025. These changes, published in Staatscourant 2026 nr. 967 on January 19, 2026, correct te...
Characterizing Burnout in Health Professionals: Insights from the BEATS Study in Portugal

By João L. Carapinha

Burnout Health Professionals: Join the BEATS Study Call Burnout health professionals in Portugal are invited to participate in the BEATS study, an initiative by the Portuguese Laboratory for Healthy Work Environments. Titled "B...
NICE Endorses Dupilumab for Eosinophilic COPD Treatment

By HEOR Staff Writer

January 26, 2026

NICE Backs Dupilumab Eosinophilic COPD Option Dupilumab eosinophilic COPD treatment gains momentum as the National Institute for Health and Care Excellence (NICE) final draft guidance recommends dupilumab as an add-on maintenance therap...
Accelerating FAST-EU Clinical Trials

By HEOR Staff Writer

FAST-EU Clinical Trials Launch with 70-Day Target The FAST-EU clinical trials pilot, known as Facilitating and Accelerating Strategic Clinical Trials in the EU, is a one-year voluntary initiative by the

North America

View All
Trump Economic Revival: Key Policies and Impacts from Davos 2026

By João L. Carapinha

January 23, 2026

Trump's Davos 2026 Economic Revival: Claimed Policy Impacts and Metrics In his special address at the World Economic Forum's Annual Meeting 2026 in Davos, Switzerland, U.S. President Donald J. Trump highlighted t...
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...
FDA Updates Labeling on Febrile Seizure Risks in Influenza Vaccine for Children

By João L. Carapinha

January 19, 2026

FDA Labeling Mandate on Febrile Seizure Risks In a significant update to vaccine safety protocols, the U.S. Food and Drug Administration (FDA) has required pediatric influenza vaccines to include warnings about an elevated risk of febri...
Guiding Principles for Ethical AI Integration in Drug Development

By HEOR Staff Writer

Guiding Principles for Ethical AI Integration in Drug Lifecycle The EMA/FDA document provides a foundational framework for ethical AI integration into drug development, emphasizing its potential to transform evidence g...

Sub-Saharan Africa

View All
Navigating Economic Resilience Through Life Sciences Investment

By João L. Carapinha

January 20, 2026

Navigating a Leaderless Global Economy Through Life Sciences Investment In an era of deepening geopolitical fragmentation, often termed the G-Zero world, global governments are urged to prioritize bold life sci...
Driving Economic Transformation through Brain Health Investment in Africa

By João L. Carapinha

January 9, 2026

The Johannesburg Communiqué from the Africa Task Force on Brain Health declares that investing in brain health is crucial, as it supports Africa’s economic transformation and Agenda 2063 goals while covering dementia, mental health, brain trauma, and substance abuse. This investment aligns with N...
mRNA Vaccine Advancements: Transforming Infectious Disease Prevention and Equity

By João L. Carapinha

January 6, 2026

Recent mRNA vaccine advancements are poised to transform global health by expanding beyond COVID-19 to tackle neglected infectious diseases and even therapeutic uses. Experts forecasting breakthroughs for 2026 highlight how these innovations use lipid nanoparticles to deliver RNA sequences encodi...
Africa Medicine Roadmap: Paving the Way for Sustainable Access to Quality Pharmaceuticals

By HEOR Staff Writer

The WHO Regional Office for Africa launched a 10-year roadmap (2025-2034) that ensures sustainable access to affordable, safe, and quality medicines while tackling high costs, supply chain issues, and substandard products. The Africa medicine roadmap builds on the African Medicines Agency (AMA), ...